Sonic Healthcare Limited (ASX:SHL)

ALERT: Price-sensitive ASX Announcement for SHL

Current share price for SHL : $21.850 0.61 (2.87%)⁺

Announcement

Half Yearly Report and Accounts

Release

19 Feb 2026 8:42AM

Price at Release

$21.240

Full Release

Summary

Sonic Healthcare Limited's half-year report for the period ending 31 December 2025 reveals a 17% increase in revenue, reaching A$5.445 billion, and an 11% rise in net profit to A$262 million. The company experienced strong organic revenue growth of 5%, supported by strategic acquisitions such as LADR in Germany and Cairo Diagnostics in the USA. The EBITDA reached A$907 million, up 10% from the previous year. Sonic Healthcare maintained its FY2026 guidance with expected EBITDA between A$1.87 to A$1.95 billion. The effective tax rate was recorded at 26.5%, and the basic earnings per share increased to 53.1 cents. The company also announced a 45-cent interim dividend, 60% franked, to be paid on 19 March 2026. The report highlights operational efficiency and synergy realization across its segments, particularly in laboratory services and radiology.

Key Points

Revenue increased by 17% to A$5.445 billion.
Net profit rose by 11% to A$262 million.
EBITDA was A$907 million, representing a 10% rise.
Organic revenue growth was 5%.
Effective tax rate was 26.5%.
Basic earnings per share increased to 53.1 cents.
Interim dividend of 45 cents, 60% franked, is payable on 19 March 2026.
FY2026 guidance with EBITDA expected between A$1.87 to A$1.95 billion.
Acquisitions included LADR in Germany and Cairo Diagnostics in the USA.
Operational efficiency and synergy realization noted in laboratory and radiology segments.

IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.